Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

Synergistic Efficacy of β-Lactam Combinations against Mycobacterium abscessus Pulmonary Infection in Mice

Elizabeth Story-Roller, Emily C. Maggioncalda, Gyanu Lamichhane
Elizabeth Story-Roller
aDivision of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily C. Maggioncalda
aDivision of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gyanu Lamichhane
aDivision of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gyanu Lamichhane
DOI: 10.1128/AAC.00614-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Mycobacterium abscessus is an emerging pathogen capable of causing invasive pulmonary infections in patients with chronic lung diseases. These infections are difficult to treat, necessitating prolonged multidrug therapy, which is further complicated by extensive intrinsic and acquired resistance exhibited by clinical M. abscessus isolates. Therefore, development of novel treatment regimens effective against drug-resistant strains is crucial. Prior studies have demonstrated synergistic efficacy of several β-lactams against M. abscessus in vitro; however, these combinations have never been tested in an animal model of M. abscessus pulmonary disease. We utilized a recently developed murine system of sustained M. abscessus lung infection delivered via an aerosol route to test the bactericidal efficacy of four novel dual β-lactam combinations and one β-lactam/β-lactamase inhibitor combination. All five of the novel combinations exhibited synergy and resulted in at least 6-log10 reductions in bacterial burden in the lungs of mice at 4 weeks compared to untreated controls (P = 0.038).

INTRODUCTION

Patients with chronic lung diseases, such as cystic fibrosis (CF) and bronchiectasis, are at increased risk for development of recurrent pulmonary infections, largely due to poor clearance of respiratory secretions, resulting in persistent colonization with pathogenic bacteria. Nontuberculous mycobacteria are ubiquitous in the environment and often colonize the airways of these patients. However, some species such as Mycobacterium abscessus can cause invasive pulmonary infections, especially in the CF population. M. abscessus infections in these patients lead to rapid decline in lung function and can significantly impair quality of life (1–3). Treatment of these infections in CF patients is a growing challenge, since M. abscessus is intrinsically resistant to several classes of antibiotics (4) and the incidence of multidrug-resistant strains is steadily rising (5–8).

Treatment of M. abscessus lung disease involves prolonged therapy with multiple antibiotics, several of which require intravenous administration and can cause substantial cytotoxicity (9, 10). Therefore, new drugs and novel regimens are urgently needed to effectively treat infections with M. abscessus strains that are resistant to drugs/regimens in current clinical use. One strategy that would allow for rapid implementation of effective treatments in the clinical setting involves repurposing of commercially available antibiotics in novel combinations. Several studies have demonstrated in vitro synergy between various antibiotics against M. abscessus, which, when used in combination, have the potential to overcome drug resistance (11–26).

One antibiotic class of particular interest along these lines is β-lactams, as they are the most widely used class of antibiotics for treatment of bacterial infections (27) and are generally well tolerated with minimal comparative cytotoxicity. There are currently only two β-lactams included in the M. abscessus treatment recommendations established by the U.S. Cystic Fibrosis Foundation and the European Cystic Fibrosis Society: cefoxitin (a cephalosporin) and imipenem (a carbapenem) (10, 28). The mechanisms of action of β-lactams against mycobacteria suggest that combinations of β-lactam subclasses should be effective against M. abscessus, but studies assessing synergy between dual β-lactams against this pathogen have only recently been undertaken and were limited to in vitro and ex vivo conditions (25, 26, 29).

β-Lactams exhibit their function via inhibition of synthesis of peptidoglycan, the exoskeleton of the bacterial cell wall that is essential for cellular growth and survival (30). The final step of peptidoglycan synthesis involves covalent bonding of monomeric peptide side chains to generate a single macromolecule that encapsulates the plasma membrane (31). Unlike most bacteria, whose peptidoglycans are predominantly cross-linked with 4→3 linkages generated by d,d-transpeptidases (DDT; also known as penicillin-binding proteins), the peptidoglycan of M. abscessus is cross-linked with both 4→3 and 3→3 linkages. These 3→3 linkages, generated by l,d-transpeptidases (LDT), predominate the peptidoglycan of M. abscessus (32).

LDTs and DDTs are differentially inhibited by β-lactam subclasses, with penicillins and cephalosporins harboring the greatest activity against DDTs and carbapenems being most active against LDTs (29, 33–35). This observation has given rise to the hypothesis that combinations of β-lactam subclasses may exhibit synergy and result in optimal killing of M. abscessus (25, 29). While the molecular mechanisms of dual β-lactam synergy have yet to be settled, it is noteworthy that these combinations have demonstrated synergistic efficacies against E. faecalis endocarditis (36) and tuberculosis (37).

M. abscessus also harbors a robust β-lactamase, BlaMab, against which many β-lactamase inhibitors are ineffective, including clavulanate, sulbactam, and tazobactam (38, 39). However, BlaMab is inactivated by the non-β-lactam β-lactamase inhibitor avibactam, resulting in the reduction of the MICs of several β-lactams against M. abscessus upon the addition of avibactam (25, 38, 40, 41). Avibactam may also directly inhibit LDTs (42), which may potentiate the synergy observed between dual β-lactams. In addition, relebactam and vaborbactam, which are also non-β-lactam β-lactamase inhibitors, reduce MICs of various β-lactams against M. abscessus when combined (43).

We recently tested these hypotheses and identified several combinations of β-lactam antibiotics that exhibited synergy against M. abscessus in vitro (25). Of these synergistic combinations, 13 were pairs of two β-lactams, and 5 consisted of a β-lactam paired with avibactam. However, since the in vitro efficacy of antibiotics against M. abscessus does not always correlate in vivo (1, 7, 44), further preclinical testing was necessary to elucidate combinations capable of treating M. abscessus pulmonary disease in an animal model.

Several attempts to establish an animal model of M. abscessus infection have been undertaken in recent years, including studies in zebrafish (45–50), Drosophila (15, 51), and Galleria mellonella larvae (52). However, these organisms are unable to mimic the complexity of mammalian physiology with regard to the treatment of infections.

A validated mouse model of chronic M. abscessus pulmonary disease resulting from an aerosol infection would be relevant in assessing efficacies of experimental treatment regimens. Prior studies of M. abscessus infection in immunocompetent mice have demonstrated gradual clearance of bacteria, while immunocompromised mice are capable of developing a sustained infection (53–56). However, in these studies, mice were infected with M. abscessus via tail vein injection, resulting in a systemic infection that is distinct from the aerosol route of infection that produces primary lung disease in humans. Attempts to establish pulmonary infection utilizing an intratracheal approach (13, 57, 58) have demonstrated sustained infections in immunocompromised mice; however, this surgical method is invasive and subject to high morbidity related to the procedure itself. Several laboratories have evaluated an aerosol route of M. abscessus infection, since it is noninvasive and mimics the route of acquisition in humans. While chronic infections were achieved in gamma interferon (59) and granulocyte-macrophage colony-stimulating factor (60) knockout mice, immunocompetent BALB/c (61) and ΔF508 “cystic fibrosis” (62) mice did not develop sustained pulmonary infections.

In order to more accurately assess pathophysiology of chronic M. abscessus lung disease in mice, a recent study leveraged the results of these prior studies, including pharmacologic immune suppression via corticosteroid injection to promote establishment of an invasive pulmonary infection in otherwise immunocompetent mice (63). C3HeB/FeJ mice were used, as they are capable of developing caseating granulomas in the setting of M. tuberculosis infection (64–66) and therefore likely also mimic the pathology caused by M. abscessus lung disease in humans. The use of injectable corticosteroids allowed for adjustment of the level of immunosuppression and chronic steroid use is considered a risk factor for invasive infections with rapidly growing mycobacteria (67–69), as well as reactivation of latent tuberculosis (70, 71), making this a clinically relevant modality. This study demonstrated that the use of dexamethasone immunosuppression in C3HeB/FeJ mice infected with M. abscessus via aerosol route allowed for establishment of an invasive M. abscessus pulmonary infection, with development of extensive alveolar inflammation with granuloma formation on histopathology following withdrawal of steroids and immune reconstitution (63). Although additional studies are needed to institute this as a standardized model of M. abscessus lung disease, this system appears to be a viable option for evaluation of in vivo treatment regimens. We therefore utilized this model to assess the in vivo efficacy of five β-lactam combinations found to be effective against M. abscessus in vitro (25).

RESULTS

Dual β-lactam combinations exhibit synergy against M. abscessus in mice.We evaluated efficacies of four novel dual β-lactam combinations and one β-lactam/β-lactamase inhibitor combination in C3HeB/FeJ mice harboring pulmonary infections with M. abscessus ATCC 19977 delivered via aerosol route. These combinations were selected based on evidence of synergy observed in vitro (25) and are as follows: imipenem and cefoxitin, imipenem and cefdinir, imipenem and doripenem, imipenem and biapenem, and biapenem and avibactam. We concurrently assessed efficacy of single drug treatments with imipenem, doripenem, biapenem, and cefdinir for comparison. Although therapeutic regimens containing imipenem or cefoxitin are used in the clinical setting to treat M. abscessus lung disease, none of these combinations have been systematically tested in an animal model against M. abscessus.

An important aspect of the dosing regimen in this study is that in dual β-lactam combinations, each β-lactam was used at only half the dose that was used in each single drug group. For instance, mice received 100 mg/kg imipenem and 20 mg/kg cefdinir per dose in this combination group, whereas single-drug-treated comparator groups received 200 mg/kg imipenem or 40 mg/kg cefdinir per dose. Our hypothesis for this dosing regimen was that, if combinations are synergistic, treatment with half dosages of each drug in a combination will produce lower bacterial burdens than the full dose of either drug when used alone.

At the onset of infection (designated week −1), the mean M. abscessus burden in the lungs of mice was 3.95 (standard deviations [SD] = 0.23) log10 CFU. After 1 week (week 0), the mean M. abscessus burden in the lungs was essentially unchanged at 3.93 (SD = 0.41) log10 CFU, and no colonies were isolated from splenic tissue; however, two colonies grew from hepatic tissue in one mouse, denoting some degree of dissemination. As demonstrated in a study describing this model (63), we observed a persistent uptrend in M. abscessus CFU in the lungs of mice that were immunosuppressed, but not receiving antibiotics throughout the experiment (Table 1). These mice were designated as “untreated” and were used as a positive control.

View this table:
  • View inline
  • View popup
TABLE 1

Mean CFU in the lungs of mice infected with M. abscessus ATCC 19977 and treated with antibiotics across 4 weeks, with associated reduction in lung CFU compared to untreated controls

At 1 week after antibiotic initiation (week 1), the average lung CFU in untreated mice was 4.61 log10 (SD = 0.73), whereas the CFU in the lungs of mice treated with antibiotic combinations all demonstrated >1-log10 reduction. By the week 2 time point, the mean lung CFU in untreated mice had increased to 6.77 log10 (SD = 1.15), whereas all antibiotic combination groups exhibited a >4-log10 reduction in mean lung CFU. At 4 weeks, the lung CFU in untreated mice was 7.55 log10 (SD = 1.63), compared to ≥6-log10 CFU reductions across all combination treatment groups. Single-drug treatments, which were administered at double the respective dosages of those in dual combinations, were also compared at this time point, with imipenem, doripenem, and biapenem conferring a >5-log10 pulmonary CFU reduction, whereas cefdinir only resulted in a 0.3-log10 decrease (Fig. 1).

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

M. abscessus CFU in the lungs of mice treated with antibiotic combinations versus single antibiotics versus untreated controls. All mice were immunosuppressed with dexamethasone. Data points represent individual mice. (A) Imipenem and cefdinir; (B) imipenem and doripenem; (C) imipenem and biapenem; (D) biapenem and avibactam.

The mean M. abscessus CFU in the liver and spleen of untreated mice at 4 weeks were 4.99 log10 (SD = 1.58) and 4.20 log10 (SD = 1.45), respectively, whereas no colonies were observed among the combination treatment groups throughout the experiment. In addition, no organ dissemination was noted among imipenem- or biapenem-treated mice; however, both liver and splenic disseminations were observed in one mouse in the doripenem group (organ cultures for the other four mice in this group were negative) and four mice in the cefdinir group. The doripenem-treated mouse with dissemination had 4.38 log10 CFU in the liver and 3.46 log10 CFU in the spleen, which averages to 0.88 log10 (SD = 1.96) CFU in the liver and 0.69 log10 (SD = 1.55) CFU in the spleen for the entire doripenem treatment group. For cefdinir-treated mice, the mean CFU counts were 3.94 log10 (SD = 2.72) and 2.97 log10 (SD = 2.33) CFU in the liver and spleen, respectively.

At 4 weeks, the difference in mean lung CFU in untreated mice versus all treatment groups was statistically significant via Kruskal-Wallis test (P = 0.001). Additional pairwise comparisons between treatment groups using the Wilcoxon rank sum test, with corrections for multiple comparisons, determined statistically significant differences in lung CFU between untreated mice and each of the combination treatment groups (P = 0.038), as well as those treated with biapenem (P = 0.038) or doripenem alone (P = 0.048), but imipenem alone did not confer a significant difference compared to untreated mice (P = 0.06). Cefdinir alone exhibited only a slight decrease in lung CFU compared to untreated controls and therefore was significantly inefficacious compared to all other treatment groups (P = 0.038).

In vitro activity versus in vivo efficacy.Although all of the antibiotic combinations tested in this study were effective, prior in vitro data (25) predicted that some combinations would perform better than others. For example, combinations of imipenem and doripenem, as well as imipenem and cefdinir, exhibited greater synergy and subsequent reduction in MICs compared to imipenem and biapenem in vitro; however, the opposite was observed in vivo. Although within the margin of error, imipenem and biapenem demonstrated a higher efficacy compared to both imipenem and doripenem and imipenem and cefdinir in mice. While antibiotic synergy was observed both in vitro and in vivo, the degree of synergy differed between testing modalities. Therefore, evaluation in an animal model enhances the rigor of results and allows for a more comprehensive evaluation of the therapeutic potential of novel combinations. That being said, dose ranging and pharmacokinetic/pharmacodynamic (PK/PD) studies are needed to optimize dosing and further characterize therapeutic levels relevant to humans.

DISCUSSION

The rising prevalence of multidrug-resistant M. abscessus strains observed among CF patients and the resulting morbidity from suboptimal treatments with cytotoxic antibiotics necessitate the urgent development of novel treatment regimens that are both effective and well tolerated. By leveraging our current understanding of the mechanisms of action of β-lactams against M. abscessus, this antibiotic class may be a largely untapped resource from which to develop these novel regimens, and their commercial availability would allow for rapid implementation in the clinical setting.

The potential for synergistic activity of dual β-lactams against mycobacteria was initially proposed based on enhanced susceptibility to amoxicillin of M. tuberculosis mutants lacking a dominant LDT (72). Subsequent studies that demonstrated similarities in molecular mechanisms of susceptibility of M. tuberculosis and M. abscessus to β-lactams (29, 32) provided the premise for potential dual β-lactam synergy against M. abscessus. Several combinations of β-lactams have demonstrated synergy against this bacterium in vitro (25, 26, 29). However, given the general lack of correlation between in vitro susceptibility and clinical efficacy (1, 7, 44), we tested five of these synergistic combinations in vivo in a recently developed murine model of M. abscessus pulmonary infection (63). This study not only provides proof of concept that this murine model is a viable option for assessment of treatment regimens against M. abscessus lung disease but also demonstrates bactericidal efficacy of these novel combinations, which have not previously been tested against this pathogen in mice.

Although most of the antibiotics tested in this study are dosed more frequently in the clinical setting (i.e., every 6 to 8 h), antibiotic administration in this experiment was limited to twice-daily dosing due to laboratory constraints. However, mice were treated 7 days per week for the duration of the experiment. With the exception of cefoxitin (54), none of the drugs tested in this study have previously been tested against M. abscessus infection in mice. Therefore, dosages were extrapolated from murine studies of other pathogens, since dose optimization studies were beyond the scope of this proof-of-concept study (73–78). As imipenem is currently used against M. abscessus in the clinical setting, the daily individual drug dose used in this study was similar to the calculated human equivalent dosage (HED) based on allometric scaling, which accounts for differences in body surface area and metabolic rate between mice and humans (79). Therefore, combination regimens included approximately half the HED of imipenem. However, because biapenem and doripenem have not previously been assessed against M. abscessus in mice, dosing concentrations tested were higher than the calculated HED but were extrapolated from prior murine studies in M. tuberculosis and K. pneumoniae, respectively (76, 78). Further studies are needed to assess PK/PD profiles and optimize antibiotic dosing; however, the efficacy demonstrated in this initial study provides a premise for future treatment studies using this murine model.

Dual β-lactam therapies are often avoided in clinical practice due to concern for potential toxicity. However, a recent meta-analysis of 13 randomized controlled trials assessed the efficacy and safety profiles of dual β-lactams compared to β-lactam plus aminoglycoside combinations against Gram-negative infections (80). This study found that dual β-lactams achieved slightly better clinical and microbiological responses, while conferring significant decreases in nephrotoxicity and ototoxicity compared to aminoglycoside-containing regimens, with the rates of other adverse events being largely comparable. Given relatively the high rate of adverse events related to current M. abscessus therapies, which often necessitate long-term use of an aminoglycoside (10), alternate treatment options associated with even a marginal reduction in cytotoxicity would be beneficial.

We found all of the novel antibiotic combinations tested to be bactericidal against M. abscessus ATCC 19977. After 4 weeks of treatment, all five combinations reduced the average lung CFU by at least 6 log10 compared to untreated controls, which was statistically significant. This not only illustrates the ability of the murine model to produce a sustained pulmonary M. abscessus infection via pharmacologic immunosuppression with dexamethasone but also provides direct examples of the bactericidal efficacy of these novel antibiotic combinations. A linear trend was observed for all treatment regimens throughout the 4-week duration of the experiment. We performed regression analysis on the data and generated trend equations that would permit prediction of time to sterilization of the infection (Table 2). This analysis predicted a linear trend, with R2 values ranging from 0.950 to 0.999, which represent correlation coefficients of the predicted trends to the actual data. Based on this analysis, we extrapolated the potential treatment duration necessary to completely clear M. abscessus infections in the lungs of mice. The combination of imipenem and biapenem was predicted to require 5.1 weeks to achieve sterilization compared to 5.3 weeks for imipenem and cefoxitin, the two β-lactams currently used to treat M. abscessus pulmonary infections in patients. It is possible that bactericidal activities of the combinations beyond the 4-week time point assessed in this study are nonlinear and require longer durations to achieve complete sterilization of M. abscessus from murine lungs. Since the aim of this study was to assess whether synergy between dual β-lactam combinations observed in vitro was preserved in vivo, determining sterilizing potential of the combinations was beyond the scope of this study, and further studies evaluating longer treatment durations are needed.

View this table:
  • View inline
  • View popup
TABLE 2

Regression analysis of observed M. abscessus burden in the lungs of mice

We also hypothesized that treatment with single drugs, at doses twice those in combination groups, would be less effective than synergistic combinations. Indeed, single-drug treatments were less effective than combinations; however, with the exception of cefdinir, all of the single-drug treatment groups exhibited a high level of bactericidal activity, with >5-log10 reductions in lung CFU at 4 weeks compared to controls. The most likely reasons for this were the relatively low initial MICs of imipenem (8 μg/ml), doripenem (16 μg/ml), and biapenem (16 μg/ml) against M. abscessus ATCC 19977, in addition to the higher than human equivalent dosages of doripenem and biapenem, as previously mentioned. Cefdinir, however, had an initial MIC of 64 μg/ml, which may explain its lack of efficacy when used alone, which was potentially further compromised by inadequate drug dosing. In addition, all of the combination groups resulted in greater CFU reductions compared to single drugs, which suggests that these combinations are synergistic in vivo, given equivalent dosing between the treatment groups.

Compared to BALB/c mice, C3HeB/FeJ mice tend to be more heterogeneous with regard to their response to both infection and treatment (66), a trait that was also observed in this study. Standard deviations in CFU among both untreated mice and those within treatment groups were initially quite small, but progressively increased throughout the course of the experiment (Table 1). This trend was particularly prevalent among untreated and single antibiotic treatment groups, resulting in higher standard deviations. In each single drug group, there was one mouse that had a much higher bacterial burden in the lungs compared to the others. For example, in the imipenem-treated group, four of five mice had lung CFU ranging from 0.0 to 1.6 log10. However, the fifth mouse had a CFU count of 5.4 log10. Similarly, for biapenem-treated mice, four of five had lung CFU counts ranging from 0.0 to 1.3 log10, whereas the CFU content in the fifth mouse was 4.7 log10. In mice treated with cefdinir, lung CFU ranges were 5.6 to 7.6 log10 for four mice, with 10.1 log10 CFU for the fifth mouse. This difference was slightly less pronounced in doripenem-treated mice, with lung CFU counts in four mice ranging from 1.0 to 3.1 log10 compared to 4.7 log10 CFU in the fifth mouse. Dissemination to the spleen or liver was only observed in one mouse in the doripenem group and four mice in the cefdinir group and did appear to correlate with higher pulmonary bacterial burdens; however, no gross pathology was observed in these mice. While heterogeneity between patients is observed in the clinical setting and the C3HeB/FeJ model may be a better representation of the varied pathophysiology expected from treatment of human infections compared to some other murine strains, additional preclinical studies with larger numbers of mice are warranted to help control for this heterogeneity.

This study illustrates proof of principle that the murine model of sustained M. abscessus pulmonary infection (63) may be a viable option for future treatment experiments but will require further optimization to improve our understanding of disease pathology. In addition, while the use of dexamethasone as an immunosuppressive agent would be relevant to patients with innate immune deficiencies or those on immunosuppressive regimens, this model is unable to mimic the complex pathophysiology of the cystic fibrosis lung with regard to impaired mucociliary clearance and biofilm formation and therefore may overemphasize the effect of antibiotic treatments. Further treatment studies in murine strains with lung pathophysiology similar to that seen in CF patients (i.e., βENaC-transgenic mice [81] that exhibit depletion of airway surface liquid due to increased sodium absorption) may provide a more accurate approximation of potential treatment efficacy in this population.

While this study assessed efficacy of novel regimens over the course of a month, we did not evaluate these regimens against a more chronic infection, nor did we assess for relapse potential after treatment cessation. Additional studies assessing rate of emergence of drug-resistant mutations after antibiotic exposure will also be important to identify combinations that are less prone to the selection of drug resistance and potentially denote greater clinical utility.

Prior in vitro work revealed several additional novel β-lactam combinations with potential efficacy against M. abscessus (25, 26, 29), which warrant further testing in vivo, in addition to studies of novel combinations against highly resistant clinical M. abscessus isolates to better assess synergistic efficacy. In addition, since the majority of antibiotics tested in this study have not previously been tested against M. abscessus in mice, the dosages were likely not optimal and therefore would necessitate dose-ranging studies to determine optimal dosages, as well as PK/PD assessments to allow for more comprehensive comparison of treatment efficacies. However, because the antibiotics tested are already commercially available and recommended dosages in humans have been established, this may not be as relevant in planning for future clinical trials.

Given our general lack of therapeutic options against M. abscessus pulmonary disease, the ability to rapidly implement novel regimens in the clinical setting will be crucial to improving patient outcomes. Use of dual β-lactams remains a novel approach to treatment of resistant infections and preliminary studies against M. abscessus both in vitro and in vivo are highly promising, warranting additional research.

MATERIALS AND METHODS

Ethics.Animal procedures used in the following studies were performed in adherence to the Johns Hopkins University Animal Care and Use Committee and to national guidelines.

Bacterial strains and growth conditions.M. abscessus reference strain ATCC 19977 was used in all studies. M. abscessus was cultured in Middlebrook 7H9 broth (Becton Dickinson) supplemented with 10% ADS (albumin, dextrose, NaCl) and 0.05% Tween 80 with constant shaking at 220 rpm in an orbital shaker at 37°C. Organ homogenates were cultured on Middlebrook 7H11 selective agar (Becton Dickinson) supplemented with 10% ADS, 50 μg/ml cycloheximide (Sigma-Aldrich), 25 μg/ml polymyxin B (Sigma-Aldrich), 50 μg/ml carbenicillin (Sigma-Aldrich), and 20 μg/ml trimethoprim (Sigma-Aldrich). Quantitative and CFU counts were enumerated after 5 days of incubation at 37°C on Middlebrook 7H11 selective agar.

Mice, infection, and corticosteroid administration.Female C3HeB/FeJ mice, 4 to 5 weeks old, were procured from Jackson Laboratories (Bar Harbor, ME). All mice were infected concurrently with 10 ml M. abscessus culture at an A600 of 0.1 via aerosolization using a Glas-Col inhalation exposure system (Glas-Col, Terre Haute, Indiana) according to the manufacturer’s instructions. The infection cycle protocol included 15 min of preheating, 30 min of nebulization, 30 min of cloud decay, and 15 min of surface decontamination.

To achieve adequate immunosuppression and ensure that any reduction in bacterial load observed in treated mice was due to antibiotic treatment rather than immune clearance, mice were treated with dexamethasone. A prior murine study demonstrated that dexamethasone is capable of adequately suppressing the immune response to achieve a sustained M. abscessus infection with an increase in pulmonary bacterial burden over time (63).

Dexamethasone (D1756; Sigma-Aldrich) was dissolved in sterile 1× phosphate-buffered saline (PBS; pH 7.4; Quality Biological) and administered via daily subcutaneous injection at 5 mg/kg/day, as described previously (63, 71, 82, 83). Daily dexamethasone treatment began 2 weeks prior to infection and was continued throughout the duration of the experiment. Mice were sacrificed at 24 h postinfection to determine the initial bacterial burden in the lungs as described above.

Antibiotic regimens.All antibiotics (imipenem, doripenem, biapenem, cefdinir, cefoxitin, avibactam, and cilastatin) were obtained through Sigma-Aldrich. Powdered drug stocks were dissolved in sterile 1× PBS to achieve the following concentrations: imipenem, 100 mg/kg; doripenem, 200 mg/kg; biapenem, 200 mg/kg; cefdinir, 20 mg/kg; cefoxitin, 200 mg/kg; and avibactam, 64 mg/kg. In addition, cilastatin was added to any regimen containing a carbapenem in a 1:1 dose ratio in an attempt to compensate for the higher activity of murine renal dihydropeptidase-1 compared to humans (84). Antibiotic regimens were administered via subcutaneous injection twice daily, 7 days a week, for a total of 4 weeks. Combination treatment groups were as follows: imipenem and cefoxitin, imipenem and cefdinir, imipenem and doripenem, imipenem and biapenem, biapenem and avibactam. Single-drug treatment groups included imipenem alone, doripenem alone, biapenem alone, and cefdinir alone. Antibiotic dosages for single-drug groups were twice those listed above to compensate for lack of a second agent. Each treatment group consisted of five mice per time point.

CFU determination.Mice treated with two drugs were sacrificed at 1, 2, and 4 weeks after treatment initiation. Mice treated with single drugs were sacrificed at 4 weeks only. Five mice per treatment group were sacrificed per time point, and the CFU burdens in the lungs, spleen, and liver were enumerated via culture as described above. Of note, homogenates of complete organs were cultured from the lungs and spleen, but only approximately 30% of hepatic tissue was homogenized and cultured; therefore, whole-liver CFU counts were extrapolated accordingly.

Data analysis.Data were analyzed via the Kruskal-Wallis rank sum test, with pairwise comparisons using a Wilcoxon rank sum test and with Bonferroni corrections for multiple comparisons.

ACKNOWLEDGMENTS

This study was supported by the Cystic Fibrosis Foundation award LAMICH17GO and National Institutes of Health award R21 AI137720 to G.L. E.S.-R. was supported by NIH T32 AI007291.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the Cystic Fibrosis Foundation or the National Institutes of Health.

FOOTNOTES

    • Received 22 March 2019.
    • Returned for modification 1 May 2019.
    • Accepted 11 May 2019.
    • Accepted manuscript posted online 20 May 2019.
  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Griffith DE,
    2. Aksamit T,
    3. Brown-Elliott BA,
    4. Catanzaro A,
    5. Daley C,
    6. Gordin F,
    7. Holland SM,
    8. Horsburgh R,
    9. Huitt G,
    10. Iademarco MF,
    11. Iseman M,
    12. Olivier K,
    13. Ruoss S,
    14. von Reyn CF,
    15. Wallace RJ, Jr,
    16. Winthrop K
    . 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175:367–416. doi:10.1164/rccm.200604-571ST.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Esther CR, Jr,
    2. Esserman DA,
    3. Gilligan P,
    4. Kerr A,
    5. Noone PG
    . 2010. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 9:117–123. doi:10.1016/j.jcf.2009.12.001.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Benwill JL,
    2. Wallace RJ, Jr
    . 2014. Mycobacterium abscessus: challenges in diagnosis and treatment. Curr Opin Infect Dis 27:506–510. doi:10.1097/QCO.0000000000000104.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Maurer FP,
    2. Bruderer VL,
    3. Ritter C,
    4. Castelberg C,
    5. Bloemberg GV,
    6. Bottger EC
    . 2014. Lack of antimicrobial bactericidal activity in Mycobacterium abscessus. Antimicrob Agents Chemother 58:3828–3836. doi:10.1128/AAC.02448-14.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Brown-Elliott BA,
    2. Wallace RJ, Jr
    . 2002. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 15:716–746. doi:10.1128/cmr.15.4.716-746.2002.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Nessar R,
    2. Cambau E,
    3. Reyrat JM,
    4. Murray A,
    5. Gicquel B
    . 2012. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 67:810–818. doi:10.1093/jac/dkr578.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. van Ingen J,
    2. Boeree MJ,
    3. van Soolingen D,
    4. Mouton JW
    . 2012. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 15:149–161. doi:10.1016/j.drup.2012.04.001.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Flume PA
    . 2016. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. J Cyst Fibros 15:139–140. doi:10.1016/S1569-1993(16)00018-7.
    OpenUrlCrossRef
  9. 9.↵
    1. Wallace RJ, Jr,
    2. Swenson JM,
    3. Silcox VA,
    4. Bullen MG
    . 1985. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 152:500–514. doi:10.1093/infdis/152.3.500.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Floto RA,
    2. Olivier KN,
    3. Saiman L,
    4. Daley CL,
    5. Herrmann JL,
    6. Nick JA,
    7. Noone PG,
    8. Bilton D,
    9. Corris P,
    10. Gibson RL,
    11. Hempstead SE,
    12. Koetz K,
    13. Sabadosa KA,
    14. Sermet-Gaudelus I,
    15. Smyth AR,
    16. van Ingen J,
    17. Wallace RJ,
    18. Winthrop KL,
    19. Marshall BC,
    20. Haworth CS
    . 2016. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 71(Suppl 1):i1–22. doi:10.1136/thoraxjnl-2015-207360.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Cremades R,
    2. Santos A,
    3. Rodriguez JC,
    4. Garcia-Pachon E,
    5. Ruiz M,
    6. Royo G
    . 2009. Mycobacterium abscessus from respiratory isolates: activities of drug combinations. J Infect Chemother 15:46–48. doi:10.1007/s10156-008-0651-y.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Shen GH,
    2. Wu BD,
    3. Hu ST,
    4. Lin CF,
    5. Wu KM,
    6. Chen JH
    . 2010. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 35:400–404. doi:10.1016/j.ijantimicag.2009.12.008.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Choi GE,
    2. Min KN,
    3. Won CJ,
    4. Jeon K,
    5. Shin SJ,
    6. Koh WJ
    . 2012. Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense. Antimicrob Agents Chemother 56:3549–3555. doi:10.1128/AAC.00685-12.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. van Ingen J,
    2. Totten SE,
    3. Helstrom NK,
    4. Heifets LB,
    5. Boeree MJ,
    6. Daley CL
    . 2012. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother 56:6324–6327. doi:10.1128/AAC.01505-12.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Oh CT,
    2. Moon C,
    3. Park OK,
    4. Kwon SH,
    5. Jang J
    . 2014. Novel drug combination for Mycobacterium abscessus disease therapy identified in a Drosophila infection model. J Antimicrob Chemother 69:1599–1607. doi:10.1093/jac/dku024.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Singh S,
    2. Bouzinbi N,
    3. Chaturvedi V,
    4. Godreuil S,
    5. Kremer L
    . 2014. In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex. Clin Microbiol Infect 20:O1124–O1127. doi:10.1111/1469-0691.12780.
    OpenUrlCrossRef
  17. 17.↵
    1. Kaushik A,
    2. Makkar N,
    3. Pandey P,
    4. Parrish N,
    5. Singh U,
    6. Lamichhane G
    . 2015. Carbapenems and rifampin exhibit synergy against Mycobacterium tuberculosis and Mycobacterium abscessus. Antimicrob Agents Chemother 59:6561–6567. doi:10.1128/AAC.01158-15.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Ferro BE,
    2. Meletiadis J,
    3. Wattenberg M,
    4. de Jong A,
    5. van Soolingen D,
    6. Mouton JW,
    7. van Ingen J
    . 2016. Clofazimine prevents the regrowth of Mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin. Antimicrob Agents Chemother 60:1097–1105. doi:10.1128/AAC.02615-15.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Mukherjee D,
    2. Wu ML,
    3. Teo JWP,
    4. Dick T
    . 2017. Vancomycin and clarithromycin show synergy against Mycobacterium abscessus in vitro. Antimicrob Agents Chemother 61:e01298-17. doi:10.1128/AAC.01298-17.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Aziz DB,
    2. Teo JWP,
    3. Dartois V,
    4. Dick T
    . 2018. Teicoplanin-tigecycline combination shows synergy against Mycobacterium abscessus. Front Microbiol 9:932. doi:10.3389/fmicb.2018.00932.
    OpenUrlCrossRef
  21. 21.↵
    1. Le Run E,
    2. Arthur M,
    3. Mainardi J-L
    . 2018. In vitro and intracellular activity of imipenem combined with tedizolid, rifabutin, and avibactam against Mycobacterium abscessus. bioRxiv doi:10.1101/411181.
    OpenUrlCrossRef
  22. 22.↵
    1. Pryjma M,
    2. Burian J,
    3. Thompson CJ
    . 2018. Rifabutin acts in synergy and is bactericidal with frontline Mycobacterium abscessus antibiotics clarithromycin and tigecycline, suggesting a potent treatment combination. Antimicrob Agents Chemother 62:e00283-18. doi:10.1128/AAC.00283-18.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Schwartz M,
    2. Fisher S,
    3. Story-Roller E,
    4. Lamichhane G,
    5. Parrish N
    . 2018. Activities of dual combinations of antibiotics against multidrug-resistant nontuberculous mycobacteria recovered from patients with cystic fibrosis. Microb Drug Resist 24:1191–1197. doi:10.1089/mdr.2017.0286.
    OpenUrlCrossRef
  24. 24.↵
    1. Zhang Z,
    2. Lu J,
    3. Song Y,
    4. Pang Y
    . 2018. In vitro activity between linezolid and other antimicrobial agents against Mycobacterium abscessus complex. Diagn Microbiol Infect Dis 90:31–34. doi:10.1016/j.diagmicrobio.2017.09.013.
    OpenUrlCrossRef
  25. 25.↵
    1. Story-Roller E,
    2. Maggioncalda EC,
    3. Lamichhane G
    . 2019. Select β-lactam combinations exhibit synergy against Mycobacterium abscessus in vitro. Antimicrob Agents Chemother 63:e02613-18. doi:10.1128/aac.02613-18.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Pandey R,
    2. Chen L,
    3. Manca C,
    4. Jenkins S,
    5. Glaser L,
    6. Vinnard C,
    7. Stone G,
    8. Lee J,
    9. Mathema B,
    10. Nuermberger EL,
    11. Bonomo RA,
    12. Kreiswirth BN
    . 2019. Dual beta-lactam combinations highly active against Mycobacterium abscessus complex in vitro. mBio 10:e02895-18. doi:10.1128/mBio.02895-18.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Hamad B
    . 2010. The antibiotics market. Nat Rev Drug Discov 9:675–676. doi:10.1038/nrd3267.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Lavollay M,
    2. Dubee V,
    3. Heym B,
    4. Herrmann JL,
    5. Gaillard JL,
    6. Gutmann L,
    7. Arthur M,
    8. Mainardi JL
    . 2014. In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex. Clin Microbiol Infect 20:O297–O300. doi:10.1111/1469-0691.12405.
    OpenUrlCrossRef
  29. 29.↵
    1. Kumar P,
    2. Chauhan V,
    3. Silva JRA,
    4. Lameira J,
    5. d’Andrea FB,
    6. Li SG,
    7. Ginell SL,
    8. Freundlich JS,
    9. Alves CN,
    10. Bailey S,
    11. Cohen KA,
    12. Lamichhane G
    . 2017. Mycobacterium abscessus l,d-transpeptidases are susceptible to inactivation by carbapenems and cephalosporins but not penicillins. Antimicrob Agents Chemother 61:e00866-17. doi:10.1128/AAC.00866-17.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Hartmann R,
    2. Holtje JV,
    3. Schwarz U
    . 1972. Targets of penicillin action in Escherichia coli. Nature 235:426–429. doi:10.1038/235426a0.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Pavelka MS, Jr,
    2. Mahapatra S,
    3. Crick DC
    . 2014. Genetics of peptidoglycan biosynthesis. Microbiol Spectr 2:MGM2-0034-2013.
    OpenUrl
  32. 32.↵
    1. Lavollay M,
    2. Fourgeaud M,
    3. Herrmann JL,
    4. Dubost L,
    5. Marie A,
    6. Gutmann L,
    7. Arthur M,
    8. Mainardi JL
    . 2011. The peptidoglycan of Mycobacterium abscessus is predominantly cross-linked by l,d-transpeptidases. J Bacteriol 193:778–782. doi:10.1128/JB.00606-10.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Dubee V,
    2. Triboulet S,
    3. Mainardi JL,
    4. Etheve-Quelquejeu M,
    5. Gutmann L,
    6. Marie A,
    7. Dubost L,
    8. Hugonnet JE,
    9. Arthur M
    . 2012. Inactivation of Mycobacterium tuberculosis l,d-transpeptidase LdtMt1 by carbapenems and cephalosporins. Antimicrob Agents Chemother 56:4189–4195. doi:10.1128/AAC.00665-12.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Cordillot M,
    2. Dubee V,
    3. Triboulet S,
    4. Dubost L,
    5. Marie A,
    6. Hugonnet JE,
    7. Arthur M,
    8. Mainardi JL
    . 2013. In vitro cross-linking of peptidoglycan by Mycobacterium tuberculosis l,d-transpeptidases and inactivation of these enzymes by carbapenems. Antimicrob Agents Chemother 57:5940–5945. doi:10.1128/AAC.01663-13.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Kumar P,
    2. Kaushik A,
    3. Lloyd EP,
    4. Li SG,
    5. Mattoo R,
    6. Ammerman NC,
    7. Bell DT,
    8. Perryman AL,
    9. Zandi TA,
    10. Ekins S,
    11. Ginell SL,
    12. Townsend CA,
    13. Freundlich JS,
    14. Lamichhane G
    . 2017. Non-classical transpeptidases yield insight into new antibacterials. Nat Chem Biol 13:54–61. doi:10.1038/nchembio.2237.
    OpenUrlCrossRef
  36. 36.↵
    1. Fernández-Hidalgo N,
    2. Almirante B,
    3. Gavaldà J,
    4. Gurgui M,
    5. Peña C,
    6. de Alarcón A,
    7. Ruiz J,
    8. Vilacosta I,
    9. Montejo M,
    10. Vallejo N,
    11. López-Medrano F,
    12. Plata A,
    13. López J,
    14. Hidalgo-Tenorio C,
    15. Gálvez J,
    16. Sáez C,
    17. Lomas JM,
    18. Falcone M,
    19. de la Torre J,
    20. Martínez-Lacasa X,
    21. Pahissa A
    . 2013. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin Infect Dis 56:1261–1268. doi:10.1093/cid/cit052.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Gonzalo X,
    2. Drobniewski F
    . 2013. Is there a place for beta-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. J Antimicrob Chemother 68:366–369. doi:10.1093/jac/dks395.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Kaushik A,
    2. Gupta C,
    3. Fisher S,
    4. Story-Roller E,
    5. Galanis C,
    6. Parrish N,
    7. Lamichhane G
    . 2017. Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus. Future Microbiol 12:473–480. doi:10.2217/fmb-2016-0234.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Soroka D,
    2. Ourghanlian C,
    3. Compain F,
    4. Fichini M,
    5. Dubee V,
    6. Mainardi JL,
    7. Hugonnet JE,
    8. Arthur M
    . 2017. Inhibition of β-lactamases of mycobacteria by avibactam and clavulanate. J Antimicrob Chemother 72:1081–1088. doi:10.1093/jac/dkw546.
    OpenUrlCrossRef
  40. 40.↵
    1. Dubee V,
    2. Bernut A,
    3. Cortes M,
    4. Lesne T,
    5. Dorchene D,
    6. Lefebvre AL,
    7. Hugonnet JE,
    8. Gutmann L,
    9. Mainardi JL,
    10. Herrmann JL,
    11. Gaillard JL,
    12. Kremer L,
    13. Arthur M
    . 2015. β-Lactamase inhibition by avibactam in Mycobacterium abscessus. J Antimicrob Chemother 70:1051–1058. doi:10.1093/jac.dku510.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Lefebvre AL,
    2. Le Moigne V,
    3. Bernut A,
    4. Veckerle C,
    5. Compain F,
    6. Herrmann JL,
    7. Kremer L,
    8. Arthur M,
    9. Mainardi JL
    . 2017. Inhibition of the beta-lactamase BlaMab by avibactam improves the in vitro and in vivo efficacy of imipenem against Mycobacterium abscessus. Antimicrob Agents Chemother 61:e02240-16. doi:10.1128/AAC.02440-16.
    OpenUrlCrossRef
  42. 42.↵
    1. Edoo Z,
    2. Iannazzo L,
    3. Compain F,
    4. Li de la Sierra Gallay I,
    5. van Tilbeurgh H,
    6. Fonvielle M,
    7. Bouchet F,
    8. Le Run E,
    9. Mainardi JL,
    10. Arthur M,
    11. Etheve-Quelquejeu M,
    12. Hugonnet JE
    . 2018. Synthesis of avibactam derivatives and activity on beta-lactamases and peptidoglycan biosynthesis enzymes of mycobacteria. Chemistry 24:8081–8086. doi:10.1002/chem.201800923.
    OpenUrlCrossRef
  43. 43.↵
    1. Kaushik A,
    2. Ammerman NC,
    3. Lee J,
    4. Martins O,
    5. Kreiswirth BN,
    6. Lamichhane G,
    7. Parrish NM,
    8. Nuermberger EL
    . 2019. In vitro activity of the new beta-lactamase inhibitors relebactam and vaborbactam in combination with beta-lactams against Mycobacterium abscessus complex clinical isolates. Antimicrob Agents Chemother 63:e02623-18. doi:10.1128/AAC.02623-18.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Philley JV,
    2. Griffith DE
    . 2013. Management of nontuberculous mycobacterial (NTM) lung disease. Semin Respir Crit Care Med 34:135–142. doi:10.1055/s-0033-1333575.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Davis JM,
    2. Clay H,
    3. Lewis JL,
    4. Ghori N,
    5. Herbomel P,
    6. Ramakrishnan L
    . 2002. Real-time visualization of mycobacterium-macrophage interactions leading to initiation of granuloma formation in zebrafish embryos. Immunity 17:693–702. doi:10.1016/S1074-7613(02)00475-2.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    1. Bernut A,
    2. Le Moigne V,
    3. Lesne T,
    4. Lutfalla G,
    5. Herrmann JL,
    6. Kremer L
    . 2014. In vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system. Antimicrob Agents Chemother 58:4054–4063. doi:10.1128/AAC.00142-14.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Bernut A,
    2. Herrmann JL,
    3. Kissa K,
    4. Dubremetz JF,
    5. Gaillard JL,
    6. Lutfalla G,
    7. Kremer L
    . 2014. Mycobacterium abscessus cording prevents phagocytosis and promotes abscess formation. Proc Natl Acad Sci U S A 111:E943–E952. doi:10.1073/pnas.1321390111.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Bernut A,
    2. Dupont C,
    3. Sahuquet A,
    4. Herrmann JL,
    5. Lutfalla G,
    6. Kremer L
    . 2015. Deciphering and imaging pathogenesis and cording of Mycobacterium abscessus in zebrafish embryos. J Vis Exp 103. doi:10.3791/53130.
    OpenUrlCrossRef
  49. 49.↵
    1. Halloum I,
    2. Carrere-Kremer S,
    3. Blaise M,
    4. Viljoen A,
    5. Bernut A,
    6. Le Moigne V,
    7. Vilcheze C,
    8. Guerardel Y,
    9. Lutfalla G,
    10. Herrmann JL,
    11. Jacobs WR, Jr,
    12. Kremer L
    . 2016. Deletion of a dehydratase important for intracellular growth and cording renders rough Mycobacterium abscessus avirulent. Proc Natl Acad Sci U S A 113:E4228–E4237. doi:10.1073/pnas.1605477113.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. Bernut A,
    2. Herrmann JL,
    3. Ordway D,
    4. Kremer L
    . 2017. The diverse cellular and animal models to decipher the physiopathological traits of Mycobacterium abscessus infection. Front Cell Infect Microbiol 7:100. doi:10.3389/fcimb.2017.00100.
    OpenUrlCrossRef
  51. 51.↵
    1. Oh CT,
    2. Moon C,
    3. Jeong MS,
    4. Kwon SH,
    5. Jang J
    . 2013. Drosophila melanogaster model for Mycobacterium abscessus infection. Microbes Infect 15:788–795. doi:10.1016/j.micinf.2013.06.011.
    OpenUrlCrossRefPubMedWeb of Science
  52. 52.↵
    1. Meir M,
    2. Grosfeld T,
    3. Barkan D
    . 2018. Establishment and validation of galleria mellonella as a novel model organism to study Mycobacterium abscessus infection, pathogenesis, and treatment. Antimicrob Agents Chemother 62:e02539-17. doi:10.1128/AAC.02539-17.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    1. Rottman M,
    2. Catherinot E,
    3. Hochedez P,
    4. Emile JF,
    5. Casanova JL,
    6. Gaillard JL,
    7. Soudais C
    . 2007. Importance of T cells, gamma interferon, and tumor necrosis factor in immune control of the rapid grower Mycobacterium abscessus in C57BL/6 mice. Infect Immun 75:5898–5907. doi:10.1128/IAI.00014-07.
    OpenUrlAbstract/FREE Full Text
  54. 54.↵
    1. Lerat I,
    2. Cambau E,
    3. Roth Dit Bettoni R,
    4. Gaillard JL,
    5. Jarlier V,
    6. Truffot C,
    7. Veziris N
    . 2014. In vivo evaluation of antibiotic activity against Mycobacterium abscessus. J Infect Dis 209:905–912. doi:10.1093/infdis/jit614.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Obregon-Henao A,
    2. Arnett KA,
    3. Henao-Tamayo M,
    4. Massoudi L,
    5. Creissen E,
    6. Andries K,
    7. Lenaerts AJ,
    8. Ordway DJ
    . 2015. Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models. Antimicrob Agents Chemother 59:6904–6912. doi:10.1128/AAC.00459-15.
    OpenUrlAbstract/FREE Full Text
  56. 56.↵
    1. Bryant JM,
    2. Grogono DM,
    3. Rodriguez-Rincon D,
    4. Everall I,
    5. Brown KP,
    6. Moreno P,
    7. Verma D,
    8. Hill E,
    9. Drijkoningen J,
    10. Gilligan P,
    11. Esther CR,
    12. Noone PG,
    13. Giddings O,
    14. Bell SC,
    15. Thomson R,
    16. Wainwright CE,
    17. Coulter C,
    18. Pandey S,
    19. Wood ME,
    20. Stockwell RE,
    21. Ramsay KA,
    22. Sherrard LJ,
    23. Kidd TJ,
    24. Jabbour N,
    25. Johnson GR,
    26. Knibbs LD,
    27. Morawska L,
    28. Sly PD,
    29. Jones A,
    30. Bilton D,
    31. Laurenson I,
    32. Ruddy M,
    33. Bourke S,
    34. Bowler IC,
    35. Chapman SJ,
    36. Clayton A,
    37. Cullen M,
    38. Daniels T,
    39. Dempsey O,
    40. Denton M,
    41. Desai M,
    42. Drew RJ,
    43. Edenborough F,
    44. Evans J,
    45. Folb J,
    46. Humphrey H,
    47. Isalska B,
    48. Jensen-Fangel S,
    49. Jönsson B,
    50. Jones AM,
    51. Katzenstein TL,
    52. Lillebaek T,
    53. MacGregor G,
    54. Mayell S,
    55. Millar M,
    56. Modha D,
    57. Nash EF,
    58. O’Brien C,
    59. O’Brien D,
    60. Ohri C,
    61. Pao CS,
    62. Peckham D,
    63. Perrin F,
    64. Perry A,
    65. Pressler T,
    66. Prtak L,
    67. Qvist T,
    68. Robb A,
    69. Rodgers H,
    70. Schaffer K,
    71. Shafi N,
    72. van Ingen J,
    73. Walshaw M,
    74. Watson D,
    75. West N,
    76. Whitehouse J,
    77. Haworth CS,
    78. Harris SR,
    79. Ordway D,
    80. Parkhill J,
    81. Floto RA
    . 2016. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science 354:751–757. doi:10.1126/science.aaf8156.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    1. Byrd TF,
    2. Lyons CR
    . 1999. Preliminary characterization of a Mycobacterium abscessus mutant in human and murine models of infection. Infect Immun 67:4700–4707.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    1. Caverly LJ,
    2. Caceres SM,
    3. Fratelli C,
    4. Happoldt C,
    5. Kidwell KM,
    6. Malcolm KC,
    7. Nick JA,
    8. Nichols DP
    . 2015. Mycobacterium abscessus morphotype comparison in a murine model. PLoS One 10:e0117657. doi:10.1371/journal.pone.0117657.
    OpenUrlCrossRef
  59. 59.↵
    1. Ordway D,
    2. Henao-Tamayo M,
    3. Smith E,
    4. Shanley C,
    5. Harton M,
    6. Troudt J,
    7. Bai X,
    8. Basaraba RJ,
    9. Orme IM,
    10. Chan ED
    . 2008. Animal model of Mycobacterium abscessus lung infection. J Leukoc Biol 83:1502–1511. doi:10.1189/jlb.1007696.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    1. De Groote MA,
    2. Johnson L,
    3. Podell B,
    4. Brooks E,
    5. Basaraba R,
    6. Gonzalez-Juarrero M
    . 2014. GM-CSF knockout mice for preclinical testing of agents with antimicrobial activity against Mycobacterium abscessus. J Antimicrob Chemother 69:1057–1064. doi:10.1093/jac/dkt451.
    OpenUrlCrossRefPubMed
  61. 61.↵
    1. Bakala N’Goma JC,
    2. Le Moigne V,
    3. Soismier N,
    4. Laencina L,
    5. Le Chevalier F,
    6. Roux AL,
    7. Poncin I,
    8. Serveau-Avesque C,
    9. Rottman M,
    10. Gaillard JL,
    11. Etienne G,
    12. Brosch R,
    13. Herrmann JL,
    14. Canaan S,
    15. Girard-Misguich F
    . 2015. Mycobacterium abscessus phospholipase C expression is induced during coculture within amoebae and enhances M. abscessus virulence in mice. Infect Immun 83:780–791. doi:10.1128/IAI.02032-14.
    OpenUrlAbstract/FREE Full Text
  62. 62.↵
    1. Le Moigne V,
    2. Rottman M,
    3. Goulard C,
    4. Barteau B,
    5. Poncin I,
    6. Soismier N,
    7. Canaan S,
    8. Pitard B,
    9. Gaillard JL,
    10. Herrmann JL
    . 2015. Bacterial phospholipases C as vaccine candidate antigens against cystic fibrosis respiratory pathogens: the Mycobacterium abscessus model. Vaccine 33:2118–2124. doi:10.1016/j.vaccine.2015.03.030.
    OpenUrlCrossRefPubMed
  63. 63.↵
    1. Maggioncalda EC,
    2. Story-Roller E,
    3. Ammerman NC,
    4. Nuermberger EL,
    5. Lamichhane G
    . 2018. Progressive Mycobacterium abscessus lung infection in C3HeB/FeJ mice associated with corticosteroid administration. bioRxiv doi:10.1101/418491:418491.
    OpenUrlCrossRef
  64. 64.↵
    1. Driver ER,
    2. Ryan GJ,
    3. Hoff DR,
    4. Irwin SM,
    5. Basaraba RJ,
    6. Kramnik I,
    7. Lenaerts AJ
    . 2012. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:3181–3195. doi:10.1128/AAC.00217-12.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Irwin SM,
    2. Driver E,
    3. Lyon E,
    4. Schrupp C,
    5. Ryan G,
    6. Gonzalez-Juarrero M,
    7. Basaraba RJ,
    8. Nuermberger EL,
    9. Lenaerts AJ
    . 2015. Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis. Dis Model Mech 8:591–602. doi:10.1242/dmm.019570.
    OpenUrlAbstract/FREE Full Text
  66. 66.↵
    1. Lanoix JP,
    2. Lenaerts AJ,
    3. Nuermberger EL
    . 2015. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis. Dis Model Mech 8:603–610. doi:10.1242/dmm.019513.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. Wallace RJ, Jr,
    2. Brown BA,
    3. Onyi GO
    . 1992. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 166:405–412. doi:10.1093/infdis/166.2.405.
    OpenUrlCrossRefPubMedWeb of Science
  68. 68.↵
    1. Ingram CW,
    2. Tanner DC,
    3. Durack DT,
    4. Kernodle GW, Jr,
    5. Corey GR
    . 1993. Disseminated infection with rapidly growing mycobacteria. Clin Infect Dis 16:463–471. doi:10.1093/clind/16.4.463.
    OpenUrlCrossRefPubMedWeb of Science
  69. 69.↵
    1. Falkinham JO, III.
    1996. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 9:177–215. doi:10.1128/CMR.9.2.177.
    OpenUrlFREE Full Text
  70. 70.↵
    1. Batten JC,
    2. Mc CR, Jr
    . 1957. The influence of corticotrophin and certain corticosteroids on populations of Mycobacterium tuberculosis in tissues of mice. Br J Exp Pathol 38:413–423.
    OpenUrlPubMedWeb of Science
  71. 71.↵
    1. Scanga CA,
    2. Mohan VP,
    3. Joseph H,
    4. Yu K,
    5. Chan J,
    6. Flynn JL
    . 1999. Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect Immun 67:4531–4538.
    OpenUrlAbstract/FREE Full Text
  72. 72.↵
    1. Gupta R,
    2. Lavollay M,
    3. Mainardi JL,
    4. Arthur M,
    5. Bishai WR,
    6. Lamichhane G
    . 2010. The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat Med 16:466–469. doi:10.1038/nm.2120.
    OpenUrlCrossRefPubMed
  73. 73.↵
    1. Alder J,
    2. Clement JJ
    . 1993. Comparative chemotherapeutic activity of temafloxacin, cefoxitin, clindamycin, imipenem and ampicillin/sulbactam against Bacteroides fragilis in a mouse subcutaneous abscess model. J Antimicrob Chemother 31:303–311. doi:10.1093/jac/31.2.303.
    OpenUrlCrossRefPubMed
  74. 74.↵
    1. Miyazaki S,
    2. Fujikawa T,
    3. Matsumoto T,
    4. Tateda K,
    5. Yamaguchi K
    . 2001. Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice. J Antimicrob Chemother 48:425–430. doi:10.1093/jac/48.3.425.
    OpenUrlCrossRefPubMed
  75. 75.↵
    1. Chambers HF,
    2. Turner J,
    3. Schecter GF,
    4. Kawamura M,
    5. Hopewell PC
    . 2005. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother 49:2816–2821. doi:10.1128/AAC.49.7.2816-2821.2005.
    OpenUrlAbstract/FREE Full Text
  76. 76.↵
    1. Hirsch EB,
    2. Guo B,
    3. Chang KT,
    4. Cao H,
    5. Ledesma KR,
    6. Singh M,
    7. Tam VH
    . 2013. Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. J Infect Dis 207:786–793. doi:10.1093/infdis/jis766.
    OpenUrlCrossRefPubMed
  77. 77.↵
    1. Berkhout J,
    2. Melchers MJ,
    3. van Mil AC,
    4. Seyedmousavi S,
    5. Lagarde CM,
    6. Nichols WW,
    7. Mouton JW
    . 2015. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice. Antimicrob Agents Chemother 59:2299–2304. doi:10.1128/AAC.04627-14.
    OpenUrlAbstract/FREE Full Text
  78. 78.↵
    1. Kaushik A,
    2. Ammerman NC,
    3. Tasneen R,
    4. Story-Roller E,
    5. Dooley KE,
    6. Dorman SE,
    7. Nuermberger EL,
    8. Lamichhane G
    . 2017. In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 72:2320–2325. doi:10.1093/jac/dkx152.
    OpenUrlCrossRef
  79. 79.↵
    1. Nair AB,
    2. Jacob S
    . 2016. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7:27–31. doi:10.4103/0976-0105.177703.
    OpenUrlCrossRefPubMed
  80. 80.↵
    1. Jiao Y,
    2. Moya B,
    3. Chen MJ,
    4. Zavascki AP,
    5. Tsai H,
    6. Tao X,
    7. Sutaria DS,
    8. Louie A,
    9. Boyce JD,
    10. Lucas DD,
    11. Kim TH,
    12. Tsuji BT,
    13. Bonomo RA,
    14. Drusano GL,
    15. Bulitta JB
    . 2019. Comparable efficacy and better safety of double beta-lactam combination therapy versus beta-lactam plus aminoglycoside in Gram-negatives: a meta-analysis of randomized, controlled trials. Antimicrob Agents Chemother doi:10.1128/AAC.00425-19.
    OpenUrlAbstract/FREE Full Text
  81. 81.↵
    1. Zhou Z,
    2. Duerr J,
    3. Johannesson B,
    4. Schubert SC,
    5. Treis D,
    6. Harm M,
    7. Graeber SY,
    8. Dalpke A,
    9. Schultz C,
    10. Mall MA
    . 2011. The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease. J Cyst Fibros 10(Suppl 2):S172–S182. doi:10.1016/S1569-1993(11)60021-0.
    OpenUrlCrossRefPubMed
  82. 82.↵
    1. Zhang M,
    2. Li SY,
    3. Rosenthal IM,
    4. Almeida DV,
    5. Ahmad Z,
    6. Converse PJ,
    7. Peloquin CA,
    8. Nuermberger EL,
    9. Grosset JH
    . 2011. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am J Respir Crit Care Med 183:1254–1261. doi:10.1164/rccm.201012-1949OC.
    OpenUrlCrossRefPubMedWeb of Science
  83. 83.↵
    1. Martins TG,
    2. Trigo G,
    3. Fraga AG,
    4. Gama JB,
    5. Longatto-Filho A,
    6. Saraiva M,
    7. Silva MT,
    8. Castro AG,
    9. Pedrosa J
    . 2012. Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection. PLoS Negl Trop Dis 6:e1925. doi:10.1371/journal.pntd.0001925.
    OpenUrlCrossRefPubMed
  84. 84.↵
    1. Rullas J,
    2. Dhar N,
    3. McKinney JD,
    4. Garcia-Perez A,
    5. Lelievre J,
    6. Diacon AH,
    7. Hugonnet JE,
    8. Arthur M,
    9. Angulo-Barturen I,
    10. Barros-Aguirre D,
    11. Ballell L
    . 2015. Combinations of beta-lactam antibiotics currently in clinical trials are efficacious in a DHP-I-deficient mouse model of tuberculosis infection. Antimicrob Agents Chemother 59:4997–4999. doi:10.1128/AAC.01063-15.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Synergistic Efficacy of β-Lactam Combinations against Mycobacterium abscessus Pulmonary Infection in Mice
Elizabeth Story-Roller, Emily C. Maggioncalda, Gyanu Lamichhane
Antimicrobial Agents and Chemotherapy Jul 2019, 63 (8) e00614-19; DOI: 10.1128/AAC.00614-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Synergistic Efficacy of β-Lactam Combinations against Mycobacterium abscessus Pulmonary Infection in Mice
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Synergistic Efficacy of β-Lactam Combinations against Mycobacterium abscessus Pulmonary Infection in Mice
Elizabeth Story-Roller, Emily C. Maggioncalda, Gyanu Lamichhane
Antimicrobial Agents and Chemotherapy Jul 2019, 63 (8) e00614-19; DOI: 10.1128/AAC.00614-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

β-lactams
Mycobacterium abscessus
synergy

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596